Mark Cuban is trying to shake up biosimilar pricing with a version of J&J's best-selling Stelara drug

Mark Cuban is trying to shake up biosimilar pricing with a version of J&J's best-selling Stelara drug

The Mark Cuban Cost Plus Drug Company will sell a cheaper version of Stelara, a J&J treatment used for chronic inflammatory and autoimmune conditions.

Mark Cuban Cost Plus Drug Co. expands access with addition of Starjemza

DALLAS – Mark Cuban Cost Plus Drug Co. (Cost Plus Drugs) announced the addition of Starjemza, a new biosimilar medication, to its growing portfolio of affordable prescription drugs. Starjemza represents another milestone in the company's mission to expand access to specialty medicines through its transparent pricing model, giving patients and providers additional options within an increasingly complex healthcare environment.The launch of Starjem…